322 related articles for article (PubMed ID: 26827603)
1. Clinical Perspectives on Targeting Therapies for Personalized Medicine.
Singer DR; Zaïr ZM
Adv Protein Chem Struct Biol; 2016; 102():79-114. PubMed ID: 26827603
[TBL] [Abstract][Full Text] [Related]
2. Using companion and coupled diagnostics within strategy to personalize targeted medicines.
Singer DR; Watkins J
Per Med; 2012 Sep; 9(7):751-761. PubMed ID: 29776269
[TBL] [Abstract][Full Text] [Related]
3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
4. Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing.
Campbell MR
Expert Rev Mol Diagn; 2020 Jun; 20(6):637-644. PubMed ID: 32167388
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenomics].
Nakatani K; Nobori T
Rinsho Byori; 2013 Nov; 61(11):1018-25. PubMed ID: 24450107
[TBL] [Abstract][Full Text] [Related]
6. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
Front Genet; 2015; 6():357. PubMed ID: 26858745
[TBL] [Abstract][Full Text] [Related]
7. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
8. International differences in companion diagnostic approvals: how are we able to manage the differences?
Shimazawa R; Ikeda M
Expert Rev Mol Diagn; 2015 Feb; 15(2):157-9. PubMed ID: 25308218
[TBL] [Abstract][Full Text] [Related]
9. Current Trends in Personalized Medicine and Companion Diagnostics: A Summary From the DIA Meeting on Personalized Medicine and Companion Diagnostics.
Tsourounis M; Stuart J; Pignato W; Toscani M; Barone J
Ther Innov Regul Sci; 2015 Jul; 49(4):530-543. PubMed ID: 30222427
[TBL] [Abstract][Full Text] [Related]
10. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
11. [Special considerations for the regulation of biological medicinal products in individualised medicine. More than stratified medicine].
Müller-Berghaus J; Volkers P; Scherer J; Cichutek K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1538-44. PubMed ID: 24170083
[TBL] [Abstract][Full Text] [Related]
12. Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine.
Zaric GS
Pharmacoeconomics; 2016 Jul; 34(7):635-44. PubMed ID: 26899833
[TBL] [Abstract][Full Text] [Related]
13. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses.
Ocana A; Ethier JL; Díez-González L; Corrales-Sánchez V; Srikanthan A; Gascón-Escribano MJ; Templeton AJ; Vera-Badillo F; Seruga B; Niraula S; Pandiella A; Amir E
Oncotarget; 2015 Nov; 6(37):39538-49. PubMed ID: 26446908
[TBL] [Abstract][Full Text] [Related]
14. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
[TBL] [Abstract][Full Text] [Related]
15. Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives.
Jørgensen JT
Trends Cancer; 2016 Dec; 2(12):706-712. PubMed ID: 28741518
[TBL] [Abstract][Full Text] [Related]
16. Cancer genomics guide clinical practice in personalized medicine.
Lehmann-Che J; Poirot B; Boyer JC; Evrard A
Therapie; 2017 Sep; 72(4):439-451. PubMed ID: 28258721
[TBL] [Abstract][Full Text] [Related]
17. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
18. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
19. Impact of Biomarkers on Personalized Medicine.
Carrigan P; Krahn T
Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258
[TBL] [Abstract][Full Text] [Related]
20. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials.
Van Heertum RL; Scarimbolo R; Ford R; Berdougo E; O'Neal M
Drug Des Devel Ther; 2015; 9():5215-23. PubMed ID: 26392755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
